PLx Pharma Inc. (PLXP) shares surged 28.56% in after-hours on Monday, July 112, 2021, and closed the daily trading at $15.98 per share. Earlier in the morning session, PLXP’s stock lost 3.27% to close Monday’s normal trading session at $12.43. PLXP shares have risen 337.68% over the last 12 months, and they have moved down 5.98% in the past week. Over the past three months, the stock has gained 26.71%, while over the past six months, it has lost105.45%.

Let’s have a brief look at its recent news.

Launch of VAZALORE in Walmart stores nationwide

On July 12, 2021, PLx Pharma Inc announced the availability of VAZALOREin 3 SKUs over 4,500 Walmart stores across the United States from mid-August.VAZALORE is the first and only U.S. Food and Drug Administration (FDA) approved liquid-filled aspirin capsules.

The three SKUs are VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.

Participation in the recent healthcare conferences

PLx Pharma Inc recently participated at the Raymond James Human Health Innovation Conference which held on Monday, June 21, 2021.

The company also took part in The JMP Securities Life Sciences Conference which held on Wednesday, June 16, 2021.

At both conferences, the company was presented by Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer.

Recent financial results announcement

On May 14, 2021, PLx Pharma Inc announced its financial results for the first quarter of 2021 which ended on March 31, 2021.

Q1 2021 financial highlights

PLx Pharma Inc reported zero revenue for Q1 2021 compared to $2,523 for the first quarter of 2020.

In Q1 2021, research and development expenses were $1.0 million compared to $0.5 million in Q1 2020.

General and administrative expenses were $2.6 million in Q1 2021 compared to $2.5 million in the first quarter of 2020.

The company suffered a net loss of $11.9 million, or $0.73 per basic and diluted share in Q1 2021, compared to net income of $1.2 million, or $0.08 per basic and diluted share, for the first quarter of 2020.

The Company had cash and cash equivalents of $84.4 million on March 31, 2021.

Q4 and FY 2020 financial results announcement

On March 12, 2021, PLx Pharma Inc announced financial results for the three months and full-year ended December 31, 2020.

Q4 2020 financial highlights

• The company earned zero revenue in Q4 2020 compared to $24,000 for the fourth quarter of 2019.
• In Q4 2020, research and development expenses were $1.2 million compared to $0.9 million in the fourth quarter of 2019.
• General and administrative expenses were $2.5 million in the fourth quarter of 2020 compared to $2.8 million in the fourth quarter of 2019.
• PLx Pharma suffered a net loss of 5 million, or $0.87 per basic and diluted share in Q4 2020, compared to a net loss of $2.3 million, or $0.25 per share, for the fourth quarter of 2019.

Conclusion

The launching of VAZALORE nationwide in Walmart stores is big news for the company due to which its stock price surged in the after-hours on Monday. We can expect it to rise significantly in the coming days.